Repligen price target lowered to $190 from $200 at JPMorgan

JPMorgan analyst Rachel Vatnsdal lowered the firm’s price target on Repligen (RGEN) to $190 from $200 and keeps an Overweight rating on the shares after the company reported a “strong top-line and bottom-line 1Q beat” while reiterating organic revenue growth guidance for the year. The firm “applauds” the company’s consistent performance during the bioprocessing recovery and continues to believe that Repligen’s portfolio positions it as “a best-in-class bioprocessing pure play,” the analyst tells investors.